Characteristics and outcomes of people living with HIV hospitalised at tertiary healthcare institutions during the COVID-19 pandemic in Mexico City DOI Creative Commons
Yanink Caro‐Vega, Lorena Guerrero‐Torres,

Andrea Cárdenas-Ortega

и другие.

BMC Infectious Diseases, Год журнала: 2024, Номер 24(1)

Опубликована: Май 24, 2024

Abstract Background While existing research on people living with HIV (PWH) during the COVID-19 pandemic primarily focused their clinical outcomes, a critical gap remains in understanding implications of delivery in-hospital care services to PWH. Our study aimed describe characteristics and outcomes PWH hospitalised 2020 Mexico City, comparing patients admitted due vs. other causes. Methods All for ≥ 24 h at four institutions City from January 1st December 31st, were included. Patients classified into two groups according leading cause first hospitalisation: or non-COVID-19. Characteristics among compared using chi-square Kruskal tests. A Cox model was used risk death after hospitalisation associated this outcome. Mortality events data 2019. Results Overall, we included 238 2020. Among them, 42 (18%) 196 (82%) non-COVID-19 causes, mainly AIDS-defining (ADE). had higher CD4 + cell counts (380 cells/mm3 [IQR: 184–580] 97 34–272], p < 0.01) proportion virologic suppression (VS) those causes (92% 55%, 0.01). The adjusted hazard ratio (aHR) AIDS 3.1 (95%CI: 1.3–7.2). not (aHR 0.9 [95%CI: 0.3–2.9]). Compared 2019, mortality significantly (19% 9%, 0.01), while hospitalisations decreased by 57%. Conclusions VS lower non-COVID-19-related who more often recently diagnosed ADEs. Most deaths related advanced disease. increased evidence impact interruption health disease pandemic. findings highlight challenges faced country where concern.

Язык: Английский

Comparative effectiveness of bictegravir versus dolutegravir, raltegravir, and efavirenz-based antiretroviral therapy among treatment-naïve individuals with HIV DOI Creative Commons
Isaac Núñez, Yanink Caro‐Vega, Conor‐James MacDonald

и другие.

European Journal of Internal Medicine, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
COVID-19 Pandemic’s Impact on HIV and AIDS Case Reporting in Peru: A Time Series Analysis of Surveillance Data (1983–2023) DOI
Yordanis Enríquez Canto

AIDS and Behavior, Год журнала: 2025, Номер unknown

Опубликована: Март 3, 2025

Язык: Английский

Процитировано

0
Comparative Effectiveness of Switching to Bictegravir From Dolutegravir-, Efavirenz-, or Raltegravir-Based Antiretroviral Therapy Among Individuals With HIV Who are Virologically Suppressed DOI Creative Commons
Isaac Núñez, Yanink Caro‐Vega, Conor‐James MacDonald

и другие.

Open Forum Infectious Diseases, Год журнала: 2024, Номер 11(8)

Опубликована: Июль 30, 2024

We aimed to determine the effectiveness of switching bictegravir in maintaining an undetectable viral load (<50 copies/mL) among people with HIV (PWH) as compared continuing dolutegravir-, efavirenz-, or raltegravir-based antiretroviral therapy using nationwide observational data from Mexico. emulated 3 target trials comparing vs dolutegravir, efavirenz, raltegravir. Eligibility criteria were PWH aged ≥16 years a <50 copies/mL and at least months current (dolutegravir, raltegravir) between July 2019 September 2021. Weekly during study period, individuals included every emulation if they continued be eligible. The main outcome was probability months, which estimated via adjusted logistic regression model. Estimated probabilities differences, 95% CIs calculated bootstrap. Outcomes also ascertained 12 sensitivity analyses performed test our analytic choices. analyzed 028 619 (63 581 unique individuals). 2.9% (95% CI, 1.9%-3.8%), 1.3% .9%-1.6%), 1.2% .8%-1.7%) higher when raltegravir, respectively. Similar results observed other analyses. Our findings suggest that could more effective suppression than

Язык: Английский

Процитировано

1
Characteristics and outcomes of people living with HIV hospitalised at tertiary healthcare institutions during the COVID-19 pandemic in Mexico City DOI Creative Commons
Yanink Caro‐Vega, Lorena Guerrero‐Torres,

Andrea Cárdenas-Ortega

и другие.

BMC Infectious Diseases, Год журнала: 2024, Номер 24(1)

Опубликована: Май 24, 2024

Abstract Background While existing research on people living with HIV (PWH) during the COVID-19 pandemic primarily focused their clinical outcomes, a critical gap remains in understanding implications of delivery in-hospital care services to PWH. Our study aimed describe characteristics and outcomes PWH hospitalised 2020 Mexico City, comparing patients admitted due vs. other causes. Methods All for ≥ 24 h at four institutions City from January 1st December 31st, were included. Patients classified into two groups according leading cause first hospitalisation: or non-COVID-19. Characteristics among compared using chi-square Kruskal tests. A Cox model was used risk death after hospitalisation associated this outcome. Mortality events data 2019. Results Overall, we included 238 2020. Among them, 42 (18%) 196 (82%) non-COVID-19 causes, mainly AIDS-defining (ADE). had higher CD4 + cell counts (380 cells/mm3 [IQR: 184–580] 97 34–272], p < 0.01) proportion virologic suppression (VS) those causes (92% 55%, 0.01). The adjusted hazard ratio (aHR) AIDS 3.1 (95%CI: 1.3–7.2). not (aHR 0.9 [95%CI: 0.3–2.9]). Compared 2019, mortality significantly (19% 9%, 0.01), while hospitalisations decreased by 57%. Conclusions VS lower non-COVID-19-related who more often recently diagnosed ADEs. Most deaths related advanced disease. increased evidence impact interruption health disease pandemic. findings highlight challenges faced country where concern.

Язык: Английский

Процитировано

0